Literature DB >> 15018839

What's atypical about atypical antipsychotic drugs?

Herbert Y Meltzer1.   

Abstract

Atypical antipsychotic drugs, by definition, differ from typical antipsychotic agents in producing significantly fewer extrapyramidal symptoms and having a lower risk of tardive dyskinesia in vulnerable clinical populations at doses that produce comparable control of psychosis. The atypical drugs differ from the typicals in their mechanism of action, but not all share the same mechanism. Many, but not all, atypicals have been found to improve cognitive function, which could be their most important advantage with regard to efficacy. Clozapine, the prototype of these agents, has been found to improve delusions and hallucinations in patients who fail to respond to other antipsychotic drugs, and to reduce the risk of suicide. These agents have been found to increase cortical dopamine and acetylcholine release, as well as have a variety of effects on the glutamatergic system not shared by the typical agents. Effects on neuronal survival and plasticity, together with decreased neurotoxicity, might also contribute to their clinical advantage over typical neuroleptic drugs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15018839     DOI: 10.1016/j.coph.2003.09.010

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  39 in total

Review 1.  Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.

Authors:  Judith Pratt; Catherine Winchester; Neil Dawson; Brian Morris
Journal:  Nat Rev Drug Discov       Date:  2012-06-22       Impact factor: 84.694

Review 2.  Integrated approaches to understanding antipsychotic drug action at GPCRs.

Authors:  Nikhil M Urs; Peter J Nicholls; Marc G Caron
Journal:  Curr Opin Cell Biol       Date:  2013-12-14       Impact factor: 8.382

3.  Predictors of smoking reduction outcomes in a sample of 287 patients with schizophrenia spectrum disorders.

Authors:  Bo-Jian Wu; Tsuo-Hung Lan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-27       Impact factor: 5.270

4.  WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics.

Authors:  Steven M Grauer; Radka Graf; Rachel Navarra; Amy Sung; Sheree F Logue; Gary Stack; Christine Huselton; Zhi Liu; Thomas A Comery; Karen L Marquis; Sharon Rosenzweig-Lipson
Journal:  Psychopharmacology (Berl)       Date:  2008-12-20       Impact factor: 4.530

Review 5.  Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia.

Authors:  Dennis H Kim; Matthew J Maneen; Stephen M Stahl
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

Review 6.  Racial and ethnic disparities in the use of antipsychotic medication: a systematic review and meta-analysis.

Authors:  Joseph H Puyat; Jamie R Daw; Colleen M Cunningham; Michael R Law; Sabrina T Wong; Devon L Greyson; Steven G Morgan
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2013-08-14       Impact factor: 4.328

7.  Pimavanserin use in a movement disorders clinic: a single-center experience.

Authors:  Abhimanyu Mahajan; Bisena Bulica; Ayesha Ahmad; Patricia Kaminski; Peter LeWitt; Danette Taylor; Shana Krstevska; Neepa Patel
Journal:  Neurol Sci       Date:  2018-07-21       Impact factor: 3.307

Review 8.  Are second generation antipsychotics a distinct class?

Authors:  Caroline Bonham; Christopher Abbott
Journal:  J Psychiatr Pract       Date:  2008-07       Impact factor: 1.325

9.  Competitive regulation of synaptic Ca2+ influx by D2 dopamine and A2A adenosine receptors.

Authors:  Michael J Higley; Bernardo L Sabatini
Journal:  Nat Neurosci       Date:  2010-07-04       Impact factor: 24.884

10.  Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia.

Authors:  Rosaria Di Lorenzo; Alice Brogli
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.